Topical emollient (moisturizer) + DUPILUMAB for pruritus

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Oct 2022: Trial registered, NCT05590585
  2. 11 Jan 2023: Trial started, NCT05590585

The trials

NCT05590585: Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

State
Completed
Phase
Phase 4
People
124 taking part
Started
11 Jan 2023
Primary completion
14 Nov 2024
Arms
dupilumab
Results
Posted on the registry
  1. 21 Oct 2022: Trial registered
  2. 11 Jan 2023: Trial started
  3. 14 Nov 2024: Trial completed
  4. 2 Jan 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.